Intel (INTC) 10-Q 27 Jul 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares shares in Millions	6 Months Ended
	Jul. 01, 2023	Jul. 21, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 01, 2023
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,188

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Income Statement [Abstract]
Net revenue	$ 12,949	$ 15,321	$ 24,664	$ 33,674
Cost of sales	8,311	9,734	16,018	18,843
Gross margin	4,638	5,587	8,646	14,831
Research and development	4,080	4,400	8,189	8,762
Marketing, general, and administrative	1,374	1,800	2,677	3,552
Restructuring and other charges	200	87	264	(1,124)
Operating expenses	5,654	6,287	11,130	11,190
Operating income (loss)	(1,016)	(700)	(2,484)	3,641
Gains (losses) on equity investments, net	(24)	(90)	145	4,233
Interest and other, net	224	(119)	365	878
Income (loss) before taxes	(816)	(909)	(1,974)	8,752
Provision for (benefit from) taxes	(2,289)	(455)	(679)	1,093
Net income (loss)	1,473	(454)	(1,295)	7,659
Less: Net income (loss) attributable to non-controlling interests	(8)	0	(18)	0
Net income (loss) attributable to Intel	$ 1,481	$ (454)	$ (1,277)	$ 7,659
Earnings per share - Basic (in dollars per share)	$ 0.35	$ (0.11)	$ (0.31)	$ 1.87
Earnings per share - Diluted (in dollars per share)	$ 0.35	$ (0.11)	$ (0.31)	$ 1.86
Weighted average shares of common stock outstanding:
Basic (shares)	4,182	4,100	4,168	4,095
Diluted (shares)	4,196	4,100	4,168	4,120

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 1,473	$ (454)	$ (1,295)	$ 7,659
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(131)	(627)	11	(742)
Actuarial valuation and other pension benefits (expenses), net	2	9	3	27
Translation adjustments and other	4	(5)	4	(30)
Other comprehensive income (loss)	(125)	(623)	18	(745)
Total comprehensive income (loss)	1,348	(1,077)	(1,277)	6,914
Less: comprehensive income (loss) attributable to non-controlling interests	(8)	0	(18)	0
Total comprehensive income (loss)	$ 1,356	$ (1,077)	$ (1,259)	$ 6,914

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,349	$ 11,144
Short-term investments	15,908	17,194
Accounts receivable, net	2,996	4,133
Inventories	11,984	13,224
Other current assets	4,119	4,712
Total current assets	43,356	50,407
Property, plant, and equipment, net of accumulated depreciation of $95,781 ($93,386 as of December 31, 2022)	90,945	80,860
Equity Investments	5,893	5,912
Goodwill	27,591	27,591
Identified intangible assets, net	5,173	6,018
Other long-term assets	12,671	11,315
Total assets	185,629	182,103
Current liabilities:
Short-term debt	2,711	4,367
Accounts payable	8,757	9,595
Accrued compensation and benefits	2,887	4,084
Income taxes payable	2,169	2,251
Other accrued liabilities	10,656	11,858
Total current liabilities	27,180	32,155
Debt	46,335	37,684
Other long-term liabilities	7,643	8,978
Contingencies (Note 13)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,188 issued and outstanding (4,137 issued and outstanding as of December 31, 2022)	34,330	31,580
Accumulated other comprehensive income (loss)	(544)	(562)
Retained earnings	67,231	70,405
Total stockholders' equity	101,017	101,423
Non-controlling interest	3,454	1,863
Accumulated other comprehensive income (loss)	104,471	103,286
Total liabilities and stockholders’ equity	$ 185,629	$ 182,103

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Assets
Accumulated depreciation	$ 95,781	$ 93,386
Stockholders’ equity:
Common stock, shares issued	4,188	4,137
Common stock, shares outstanding		4,137

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 11,144	$ 4,827
Cash flows provided by (used for) operating activities:
Net income (loss)	(1,295)	7,659
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	3,733	5,528
Share-based compensation	1,661	1,599
Restructuring and other charges	255	73
Amortization of intangibles	909	968
(Gains) losses on equity investments, net	(146)	(4,230)
(Gains) losses on divestitures	0	(1,072)
Changes in assets and liabilities:
Accounts receivable	1,137	3,397
Inventories	1,240	(1,386)
Accounts payable	(1,102)	117
Accrued compensation and benefits	(1,340)	(1,985)
Income taxes	(2,186)	(2,232)
Other assets and liabilities	(1,843)	(1,736)
Total adjustments	2,318	(959)
Net cash provided by operating activities	1,023	6,700
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(13,301)	(11,846)
Purchases of short-term investments	(25,696)	(25,514)
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	26,957	25,407
Sales of equity investments	253	4,775
Proceeds from divestiture	0	6,579
Other investing	458	(1,820)
Net cash used for investing activities	(11,329)	(2,419)
Cash flows provided by (used for) financing activities:
Repayment of commercial paper	(3,944)	0
Payments on finance leases	(96)	(299)
Partner contributions	834	0
Proceeds from sales of subsidiary shares	1,573	0
Issuance of long-term debt, net of issuance costs	10,968	0
Repayment of debt	0	(1,688)
Payment of dividends to stockholders	(2,036)	(2,986)
Other financing	212	255
Net cash provided by (used for) financing activities	7,511	(4,718)
Net increase (decrease) in cash and cash equivalents	(2,795)	(437)
Cash and cash equivalents, end of period	8,349	4,390
Supplemental disclosures:
Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities	5,113	3,286
Interest, net of capitalized interest	393	214
Income taxes, net of refunds	$ 1,520	$ 3,326

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock and Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interest
Common stock, shares outstanding, beginning (in shares) at Dec. 25, 2021		4,070
Total stockholders' equity, beginning at Dec. 25, 2021	$ 95,391	$ 28,006	$ (880)	$ 68,265	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	7,659			7,659
Other comprehensive income (loss)	(745)		(745)
Employee equity incentive plans and other (in shares)		42
Employee equity incentive plans and other	601	$ 601
Share-based compensation	1,599	$ 1,599
Restricted stock unit withholdings (in shares)		(6)
Restricted stock unit withholdings	(301)	$ (348)		47
Cash dividends declared	(2,986)			(2,986)
Common stock, shares outstanding, ending (in shares) at Jul. 02, 2022		4,106
Total stockholders' equity, ending at Jul. 02, 2022	101,218	$ 29,858	(1,625)	72,985	0
Common stock, shares outstanding, beginning (in shares) at Apr. 02, 2022		4,089
Total stockholders' equity, beginning at Apr. 02, 2022	103,136	$ 29,244	(1,002)	74,894	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(454)			(454)
Other comprehensive income (loss)	(623)		(623)
Employee equity incentive plans and other (in shares)		22
Employee equity incentive plans and other	12	$ 12
Share-based compensation	892	$ 892
Restricted stock unit withholdings (in shares)		(5)
Restricted stock unit withholdings	(246)	$ (290)		44
Cash dividends declared	(1,499)			(1,499)
Common stock, shares outstanding, ending (in shares) at Jul. 02, 2022		4,106
Total stockholders' equity, ending at Jul. 02, 2022	$ 101,218	$ 29,858	(1,625)	72,985	0
Common stock, shares outstanding, beginning (in shares) at Dec. 31, 2022	4,137	4,137
Total stockholders' equity, beginning at Dec. 31, 2022	$ 103,286	$ 31,580	(562)	70,405	1,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(1,295)			(1,277)	(18)
Other comprehensive income (loss)	18		18
Net proceeds from sales of subsidiary shares and partner contributions	2,407	$ 866			1,541
Employee equity incentive plans and other (in shares)		58
Employee equity incentive plans and other	665	$ 665
Share-based compensation	1,661	$ 1,593			68
Restricted stock unit withholdings (in shares)		(7)
Restricted stock unit withholdings	(235)	$ (374)		139
Cash dividends declared	(2,036)			(2,036)
Common stock, shares outstanding, ending (in shares) at Jul. 01, 2023		4,188
Total stockholders' equity, ending at Jul. 01, 2023	104,471	$ 34,330	(544)	67,231	3,454
Common stock, shares outstanding, beginning (in shares) at Apr. 01, 2023		4,171
Total stockholders' equity, beginning at Apr. 01, 2023	100,403	$ 32,829	(419)	65,649	2,344
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	1,473			1,481	(8)
Other comprehensive income (loss)	(125)		(125)
Net proceeds from sales of subsidiary shares and partner contributions	1,958	$ 866			1,092
Employee equity incentive plans and other (in shares)		22
Employee equity incentive plans and other	6	$ 6
Share-based compensation	922	$ 896			26
Restricted stock unit withholdings (in shares)		(5)
Restricted stock unit withholdings	(166)	$ (267)		101
Common stock, shares outstanding, ending (in shares) at Jul. 01, 2023		4,188
Total stockholders' equity, ending at Jul. 01, 2023	$ 104,471	$ 34,330	$ (544)	$ 67,231	$ 3,454

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) - $ / shares	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Retained Earnings
Cash dividends declared (in dollars per share)	$ 0.49	$ 0.73

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jul. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. We have a 52- or 53-week fiscal year that ends on the last Saturday in December. Fiscal year 2023 is a 52-week fiscal year; fiscal 2022 was a 53-week fiscal year, with the extra week included in the first quarter of 2022. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the Consolidated Financial Statements in our 2022 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	6 Months Ended
	Jul. 01, 2023
Segment Reporting [Abstract]
Operating Segments	Note 2 : Operating Segments We previously announced the organizational change to integrate AXG into CCG and DCAI. This change is intended to drive a more effective go-to-market capability and to accelerate the scale of these businesses, while also reducing costs. As a result, we modified our segment reporting in the first quarter of 2023 to align to this and certain other business reorganizations. All prior-period segment data has been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance starting in fiscal year 2023. We manage our business through the following operating segments: ▪ Client Computing (CCG) ▪ Data Center and AI (DCAI) ▪ Network and Edge (NEX) ▪ Mobileye ▪ Intel Foundry Services (IFS) We derive a substantial majority of our revenue from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which is based on Intel ® architecture. CCG, DCAI and NEX are our reportable operating segments. Mobileye and IFS do not qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. When we enter into federal contracts, they are aligned to the sponsoring operating segment. We have sales and marketing, manufacturing, engineering, finance, and administration groups. Expenses for these groups are generally allocated to the operating segments. We have an "all other" category that includes revenue, expenses, and charges such as: ▪ results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives; ▪ historical results of operations from divested businesses; ▪ amounts included within restructuring and other charges ; ▪ employee benefits, compensation, impairment charges, and other expenses not allocated to the operating segments; and ▪ acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). The CODM does not evaluate operating segments using discrete asset information, and we do not identify or allocate assets by operating segments. Based on the interchangeable nature of our manufacturing and assembly and test assets, most of the related depreciation expense is not directly identifiable within our operating segments, as it is included in overhead cost pools and subsequently absorbed into inventory as each product passes through our manufacturing process. Because our products are then sold across multiple operating segments, it is impracticable to determine the total depreciation expense included as a component of each operating segment's operating income (loss) results. We do not allocate gains and losses from equity investments, interest and other income, share-based compensation, or taxes to our operating segments. Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. There have been no changes to our segment accounting policies disclosed in our 2022 Form 10-K except for the organizational change described above. Net revenue and operating income (loss) for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net revenue: Client Computing Desktop $ 2,370 $ 2,289 $ 4,249 $ 4,930 Notebook 3,896 4,751 7,303 10,710 Other 514 638 995 1,360 6,780 7,678 12,547 17,000 Data Center and AI 4,004 4,695 7,722 10,769 Network and Edge 1,364 2,211 2,853 4,350 Mobileye 454 460 912 854 Intel Foundry Services 232 57 350 213 All other 115 220 280 488 Total net revenue $ 12,949 $ 15,321 $ 24,664 $ 33,674 Operating income (loss): Client Computing $ 1,039 $ 876 $ 1,559 $ 3,598 Data Center and AI (161) (80) (679) 1,313 Network and Edge (187) 294 (487) 710 Mobileye 129 190 252 338 Intel Foundry Services (143) (134) (283) (157) All other (1,693) (1,846) (2,846) (2,161) Total operating income (loss) $ (1,016) $ (700) $ (2,484) $ 3,641 In the second quarter of 2022, we initiated the wind-down of our Intel® Optane™ memory business, which is part of our DCAI operating segment, resulting in an inventory impairment of $559 million in Cost of sales

Non-Controlling Interests

Non-Controlling Interests	6 Months Ended
	Jul. 01, 2023
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Note 3 : Non-Controlling Interests Semiconductor Co-Investment Program In 2022, we closed a transaction with Brookfield Asset Management (Brookfield) resulting in the formation of Arizona Fab LLC (Arizona Fab), a VIE for which we and Brookfield own 51% and 49%, respectively. Because we are the primary beneficiary of the VIE, we fully consolidate the results of Arizona Fab into our consolidated financial statements. Generally, contributions will be made to, and distributions will be received from, Arizona Fab based on both parties' proportional ownership. We will be sole operator and majority owner of two new chip factories that will be constructed by Arizona Fab, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona Fab at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties. We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona Fab of $29.0 billion. As of July 1, 2023, a substantial majority of the assets of Arizona Fab consisted of property, plant, and equipment. The assets held by Arizona Fab, which can be used only to settle obligations of the VIE and are not available to us, were $3.5 billion as of July 1, 2023 ($1.8 billion as of December 31, 2022). Non-controlling interest in Arizona Fab was $1.7 billion as of July 1, 2023 ($874 million as of December 31, 2022). Net loss attributable to non-controlling interest in Arizona Fab was $3 million in the second quarter of 2023 and $8 million in the first six months of 2023; there was no net income (loss) attributable to non-controlling interest in the first six months of 2022. Mobileye In October 2022, Mobileye completed its IPO and certain other equity financing transactions that resulted in net proceeds of $1.0 billion. During the second quarter of 2023, we converted $38.5 million of class B shares into class A shares, representing 5% of Mobileye’s outstanding capital stock, and subsequently sold the class A shares for $42 per share as part of a secondary offering. We received net proceeds of $1.6 billion and increased our capital in excess of par value by $866 million as a result of the secondary offering. As of July 1, 2023, Intel held approximately 88% (94% as of December 31, 2022) of the outstanding equity interest in Mobileye. Non-controlling interest in Mobileye was $1.8 billion as of July 1, 2023 ($1.0 billion as of December 31, 2022). Net loss attributable to non-controlling interest in Mobileye was $5 million in the second quarter of 2023 and $10 million in the first six months of 2023; there was no net income (loss) attributable to non-controlling interest in the first six months of 2022. IMS Nanofabrication In June 2023, we signed an agreement with Bain Capital Special Situations to sell an approximately 20% minority stake in our IMS Nanofabrication GmbH (IMS) business, a business within our IFS operating segment. Following the closure of the transaction, which is expected to occur in the third quarter of 2023, we will continue to consolidate the results of IMS into our consolidated financial statements. The transaction is expected to accelerate the innovation of critical technologies and foster deeper cross-industry collaboration.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 4 : Earnings (Loss) Per Share We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended Six Months Ended (In Millions, Except Per Share Amounts) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net income (loss) $ 1,473 $ (454) $ (1,295) $ 7,659 Less: Net income (loss) attributable to non-controlling interests (8) — (18) — Net income (loss) attributable to Intel 1,481 (454) (1,277) 7,659 Weighted average shares of common stock outstanding—basic 4,182 4,100 4,168 4,095 Dilutive effect of employee equity incentive plans 14 — — 25 Weighted average shares of common stock outstanding—diluted 4,196 4,100 4,168 4,120 Earnings (loss) per share attributable to Intel—basic $ 0.35 $ (0.11) $ (0.31) $ 1.87 Earnings (loss) per share attributable to Intel—diluted $ 0.35 $ (0.11) $ (0.31) $ 1.86 Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. Due to our net losses for the six months ended July 1, 2023 and for the three months ended July 2, 2022, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan had an anti-dilutive effect on diluted loss per share for those periods and were excluded. Securities that were anti-dilutive were insignificant and were excluded from the computation of diluted earnings per share in all periods presented.

Other Financial Statement Detai

Other Financial Statement Details	6 Months Ended
	Jul. 01, 2023
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $1.0 billion during the first six months of 2023, and we did not factor accounts receivable during the first six months of 2022. After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories (In Millions) Jul 1, 2023 Dec 31, 2022 Raw materials $ 1,284 $ 1,517 Work in process 6,638 7,565 Finished goods 4,062 4,142 Total inventories $ 11,984 $ 13,224 Other Accrued Liabilities Other accrued liabilities include deferred compensation of $2.7 billion as of July 1, 2023 ($2.4 billion as of December 31, 2022). Interest and Other, Net Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Interest income $ 313 $ 98 $ 647 $ 145 Interest expense (214) (109) (407) (233) Other, net 125 (108) 125 966 Total interest and other, net $ 224 $ (119) $ 365 $ 878 Interest expense is net of $381 million of interest capitalized in the second quarter of 2023 and $744 million in the first six months of 2023 ($154 million in the second quarter of 2022 and $296 million in the first six months of 2022). Other, net includes a gain in 2022 of $1.0 billion resulting from the first closing of the divestiture of our NAND memory business.

Restructuring and Other Charges

Restructuring and Other Charges	6 Months Ended
	Jul. 01, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Employee severance and benefit arrangements $ 171 $ 38 $ 132 $ 43 Litigation charges and other 20 13 97 (1,203) Asset impairment charges 9 36 35 36 Total restructuring and other charges $ 200 $ 87 $ 264 $ (1,124) The 2022 Restructuring Program was approved in the third quarter of 2022 to rebalance our workforce and operations to create efficiencies and improve our product execution in alignment with our strategy. We expect these actions to be substantially completed by the end of 2023, but this is subject to change. Any changes to the estimates or timing of executing the 2022 Restructuring Program will be reflected in our results of operations. Restructuring activity for the 2022 Restructuring Program during the first six months of 2023 was as follows: (In Millions) Accrued restructuring balance as of December 31, 2022 $ 873 Additional accruals 101 Adjustments 26 Cash payments (742) Accrued restructuring balance as of July 1, 2023 $ 258 The accrued restructuring balances as of July 1, 2023 and December 31, 2022 were recorded as current liabilities within accrued compensation and benefits on the Consolidated Condensed Balance Sheets . The cumulative cost of the 2022 Restructuring Program as of July 1, 2023 was $1.2 billion. Litigation charges and other includes a $1.2 billion benefit in the first six months of 2022 from the annulled penalty related to an EC fine that was recorded and paid in 2009. Refer to "Note 13: Contingencies" within the Notes to Consolidated Condensed Financial Statements for further information on legal proceedings related to the EC fine.

Income Taxes

Income Taxes	6 Months Ended
	Jul. 01, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 : Income Taxes Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Income (loss) before taxes $ (816) $ (909) $ (1,974) $ 8,752 Provision for (benefit from) taxes $ (2,289) $ (455) $ (679) $ 1,093 Effective tax rate 280.5 % 50.1 % 34.4 % 12.5 % Our provision for, or benefit from, income taxes for an interim period has historically been determined using an estimated annual effective tax rate, adjusted for discrete items, if any. Under certain circumstances where we are unable to make a reliable estimate of the annual effective tax rate, we use the actual effective tax rate for the year-to-date period. In the second quarter of 2023 , we used this approach due to the variability of the rate as a result of fluctuations in forecasted income and the effects of being taxed in multiple tax jurisdictions.

Investments

Investments	6 Months Ended
	Jul. 01, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Note 8 : Investments Short-term Investments Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments. Government debt includes instruments such as non-US government bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of July 1, 2023, and December 31, 2022, substantially all time deposits were issued by institutions outside the US. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net . The fair value of our hedged investments was $14.7 billion as of July 1, 2023 ($16.2 billion as of December 31, 2022). For hedged investments still held at the reporting date, we recorded net losses of $183 million in the second quarter of 2023 and net losses of $91 million in the first six months of 2023 ($1.0 billion of net losses in the second quarter of 2022 and $1.3 billion of net losses in the first six months of 2022). We recorded net gains on the related derivatives of $237 million in the second quarter of 2023 and net gains of $124 million in the first six months of 2023 ($868 million of net gains in the second quarter of 2022 and net gains of $1.2 billion in the first six months of 2022). Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) . The adjusted cost of our unhedged investments was $6.9 billion as of July 1, 2023 ($10.2 billion as of December 31, 2022), which approximated the fair value for these periods. The fair value of marketable debt investments, by contractual maturity, as of July 1, 2023, was as follows: (In Millions) Fair Value Due in 1 year or less $ 10,441 Due in 1–2 years 1,958 Due in 2–5 years 5,352 Due after 5 years 725 Instruments not due at a single maturity date 1 3,142 Total $ 21,618 1 Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents. Equity Investments (In Millions) Jul 1, 2023 Dec 31, 2022 Marketable equity securities 1 $ 1,295 $ 1,341 Non-marketable equity securities 4,589 4,561 Equity method investments 9 10 Total $ 5,893 $ 5,912 1 Over 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. The trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange. The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Ongoing mark-to-market adjustments on marketable equity securities $ (85) $ (209) $ 103 $ (639) Observable price adjustments on non-marketable equity securities — 135 10 206 Impairment charges (38) (44) (74) (67) Sale of equity investments and other 1 99 28 106 4,733 Total gains (losses) on equity investments, net $ (24) $ (90) $ 145 $ 4,233 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions. Net unrealized gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net unrealized gains (losses) recognized during the period on equity securities $ (26) $ (93) $ 141 $ (337) Less: Net (gains) losses recognized during the period on equity securities sold during the period 28 (19) (7) (11) Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 2 $ (112) $ 134 $ (348) McAfee Corp.

Acquisitions and Divestitures

Acquisitions and Divestitures	6 Months Ended
	Jul. 01, 2023
Business Combinations [Abstract]
Acquisitions and Divestitures	Note 9 : Acquisitions and Divestitures Acquisitions Acquisition of Tower Semiconductor During the first quarter of 2022 , we entered into a definitive agreement to acquire Tower Semiconductor Ltd. (Tower) in a cash-for-stock transaction. Tower is a leading foundry for analog semiconductor solutions. The acquisition is intended to advance our IDM 2.0 strategy by accelerating our global end-to-end foundry business. Under the agreement, each issued and outstanding ordinary share of Tower would be converted at closing into the right to receive $53 per share in cash, representing a total enterprise value of approximately $5.4 billion as of the agreement date. We continue to work to close the transaction, which remains subject to certain regulatory approvals and customary closing conditions. If regulatory approvals are not received prior to August 15, 2023, and the agreement is terminated by either party, we may be obligated to pay Tower a termination fee of $353 million. If the acquisition is completed, Tower will be included in our IFS operating segment. Divestitures NAND Memory Business On December 29, 2021, we closed the first phase of our agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business for $9.0 billion in cash. Our NAND memory business includes our NAND memory technology and manufacturing business (the NAND OpCo Business), of which we deconsolidated our ongoing interests in as part of the sale . The transaction will be completed in two closings and upon the first closing in the first quarter of 2022, SK hynix paid $7.0 billion of consideration and we recognized a pre-tax gain of $1.0 billion within interest and other, net , and tax expense of $495 million. We recorded a receivable in other long-term assets for the remaining proceeds of $1.9 billion which remains outstanding as of July 1, 2023, and will be received upon the second closing of the transaction, expected to be no earlier than March 2025. The wafer manufacturing and sale agreement includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to $500 million annually, and $1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business in light of the current business environment and projections, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics. As of July 1, 2023, we also have a receivable due from the NAND OpCo Business, a deconsolidated entity, of $201 million recorded within other current assets

Borrowings

Borrowings	6 Months Ended
	Jul. 01, 2023
Debt Disclosure [Abstract]
Borrowings	Note 10 : Borrowings In the first quarter of 2023, we issued a total of $11.0 billion aggregate principal amount of senior notes. We also amended both our 5-year $5.0 billion revolving credit facility agreement, extending the maturity date by one year to March 2028, and our 364-day $5.0 billion credit facility agreement, extending the maturity date to March 2024. The revolving credit facilities had no borrowings outstanding as of July 1, 2023. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. In the first six months of 2023, we settled in cash $3.9 billion of our commercial paper. We had no outstanding commercial paper as of July 1, 2023 ($3.9 billion as of December 31, 2022). Our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

Fair Value

Fair Value	6 Months Ended
	Jul. 01, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 11 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Jul 1, 2023 Dec 31, 2022 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 1,077 $ — $ 1,077 $ — $ 856 $ — $ 856 Financial institution instruments¹ 3,046 1,587 — 4,633 6,899 1,474 — 8,373 Reverse repurchase agreements — 1,700 — 1,700 — 1,301 — 1,301 Short-term investments: Corporate debt — 6,158 — 6,158 — 5,381 — 5,381 Financial institution instruments¹ 96 3,731 — 3,827 196 4,729 — 4,925 Government debt² 49 5,874 — 5,923 48 6,840 — 6,888 Other current assets: Derivative assets 197 963 — 1,160 — 1,264 — 1,264 Loans receivable — 55 — 55 — 53 — 53 Marketable equity securities 1,295 — — 1,295 1,341 — — 1,341 Other long-term assets: Derivative assets — 5 — 5 — 10 — 10 Total assets measured and recorded at fair value $ 4,683 $ 21,150 $ — $ 25,833 $ 8,484 $ 21,908 $ — $ 30,392 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 446 $ 101 $ 547 $ 111 $ 485 $ 89 $ 685 Other long-term liabilities: Derivative liabilities — 722 — 722 — 699 — 699 Total liabilities measured and recorded at fair value $ — $ 1,168 $ 101 $ 1,269 $ 111 $ 1,184 $ 89 $ 1,384 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant, and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, reverse repurchase agreements with original maturities greater than three months, and issued debt. We classify the fair value of grants receivable and reverse repurchase agreements with original maturities greater than three months as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of July 1, 2023 was $512 million (the aggregate carrying value as of December 31, 2022 was $437 million). We have no reverse repurchase agreements as of July 1, 2023 (the aggregate carrying value as of December 31, 2022 was $400 million).

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	6 Months Ended
	Jul. 01, 2023
Equity [Abstract]
Other Comprehensive Income (Loss)	Note : Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first six months of 2023 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 31, 2022 $ (299) $ (259) $ (4) $ (562) Other comprehensive income (loss) before reclassifications (191) — 5 (186) Amounts reclassified out of accumulated other comprehensive income (loss) 218 3 — 221 Tax effects (16) — (1) (17) Other comprehensive income (loss) 11 3 4 18 Balance as of July 1, 2023 $ (288) $ (256) $ — $ (544) We estimate that we will reclassify approximately $110 million (before taxes) of net derivative losses from accumulated other comprehensive income (loss)

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jul. 01, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 12 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Jul 1, 2023 Dec 31, 2022 Foreign currency contracts $ 27,267 $ 31,603 Interest rate contracts 17,356 16,011 Other 2,058 2,094 Total $ 46,681 $ 49,708 Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Jul 1, 2023 Dec 31, 2022 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 144 $ 347 $ 142 $ 290 Interest rate contracts — 798 — 777 Total derivatives designated as hedging instruments $ 144 $ 1,145 $ 142 $ 1,067 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 497 $ 118 $ 866 $ 194 Interest rate contracts 327 6 266 12 Equity contracts 197 — — 111 Total derivatives not designated as hedging instruments $ 1,021 $ 124 $ 1,132 $ 317 Total derivatives $ 1,165 $ 1,269 $ 1,274 $ 1,384 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Jul 1, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,070 $ — $ 1,070 $ (548) $ (522) $ — Reverse repurchase agreements 1,700 — 1,700 — (1,700) — Total assets $ 2,770 $ — $ 2,770 $ (548) $ (2,222) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Total liabilities $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges recognized in other comprehensive income (loss) were $245 million net losses in the second quarter of 2023 and $191 million net losses in the first six months of 2023 ($782 million net losses in the second quarter of 2022 and $897 million net losses in the first six months of 2022). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first six months of 2023 and 2022, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Interest rate contracts $ (213) $ (236) $ (21) $ (947) Hedged items 213 236 21 947 Total $ — $ — $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Jul 1, 2023 Dec 31, 2022 Jul 1, 2023 Dec 31, 2022 Long-term debt $ (11,200) $ (11,221) $ 797 $ 776 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of July 1, 2023 and December 31, 2022. Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Six Months Ended (In Millions) Location of Gains (Losses) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Foreign currency contracts Interest and other, net $ 211 $ 1,023 $ 212 $ 1,181 Interest rate contracts Interest and other, net 124 31 90 125 Other Various 100 (331) 215 (465) Total $ 435 $ 723 $ 517 $ 841

Contingencies

Contingencies	6 Months Ended
	Jul. 01, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 13 : Contingencies Legal Proceedings We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. We have accrued a charge of $2.2 billion related to litigation involving VLSI, described below. Excluding the VLSI claims, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009. We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC’s 2009 findings against us regarding rebates, as well as the fine imposed on Intel, which was returned to us in February 2022. In April 2022, the EC appealed the General Court’s decision to the Court of Justice. A hearing date on the appeal has not been scheduled. The General Court’s January 2022 decision did not annul the EC’s 2009 finding that we made payments to prevent sales of specific rival products, and in January 2023 the EC reopened its administrative procedure to determine a fine against us based on that alleged conduct. Given the procedural posture and the nature of this proceeding we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from this matter. In a related matter, in April 2022 we filed applications with the General Court seeking an order requiring the EC to pay us approximately €593 million in default interest, which applications have been stayed pending the EC’s appeal of the General Court’s January 2022 decision. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. Numerous lawsuits have been filed against us relating to Spectre, Meltdown, and other variants of the security vulnerabilities that have been identified since 2018. As of July 26, 2023, consumer class action lawsuits against us were pending in the US, Canada, and Argentina. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs’ failure to plead a viable claim. Plaintiffs have appealed that decision to the Ninth Circuit Court of Appeals. In Canada, an initial status conference has not yet been scheduled in one case pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. In Argentina, Intel Argentina was served with, and responded to, a class action complaint in June 2022. The Argentinian court dismissed plaintiffs’ claims for lack of standing in May 2023, and plaintiffs have appealed. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. Litigation Related to 7nm Product Delay Announcement Multiple securities class action lawsuits were filed in the US District Court for the Northern District of California against us and certain officers following our July 2020 announcement of 7nm product delays. The court consolidated the lawsuits and appointed lead plaintiffs in October 2020, and in January 2021 plaintiffs filed a consolidated complaint. Plaintiffs purport to represent all persons who purchased or otherwise acquired our common stock from October 25, 2019 through October 23, 2020, and they generally allege that defendants violated the federal securities laws by making false or misleading statements about the timeline for 7nm products. In March 2023, the court granted the defendants’ motion to dismiss the consolidated complaint, and in April 2023 entered judgment. Plaintiffs have appealed. Given the procedural posture and the nature of the case, including that it is in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class being certified or the ultimate size of any class if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter. In July 2021, we introduced a new process node naming structure, and the 7nm process is now called Intel 4. Litigation Related to Patent and IP Claims We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,481	$ (454)	$ (1,277)	$ 7,659

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jul. 01, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Operating Segments (Tables)

Operating Segments (Tables)	6 Months Ended
	Jul. 01, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenue and operating income (loss) for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net revenue: Client Computing Desktop $ 2,370 $ 2,289 $ 4,249 $ 4,930 Notebook 3,896 4,751 7,303 10,710 Other 514 638 995 1,360 6,780 7,678 12,547 17,000 Data Center and AI 4,004 4,695 7,722 10,769 Network and Edge 1,364 2,211 2,853 4,350 Mobileye 454 460 912 854 Intel Foundry Services 232 57 350 213 All other 115 220 280 488 Total net revenue $ 12,949 $ 15,321 $ 24,664 $ 33,674 Operating income (loss): Client Computing $ 1,039 $ 876 $ 1,559 $ 3,598 Data Center and AI (161) (80) (679) 1,313 Network and Edge (187) 294 (487) 710 Mobileye 129 190 252 338 Intel Foundry Services (143) (134) (283) (157) All other (1,693) (1,846) (2,846) (2,161) Total operating income (loss) $ (1,016) $ (700) $ (2,484) $ 3,641 In the second quarter of 2022, we initiated the wind-down of our Intel® Optane™ memory business, which is part of our DCAI operating segment, resulting in an inventory impairment of $559 million in Cost of sales

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended (In Millions, Except Per Share Amounts) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net income (loss) $ 1,473 $ (454) $ (1,295) $ 7,659 Less: Net income (loss) attributable to non-controlling interests (8) — (18) — Net income (loss) attributable to Intel 1,481 (454) (1,277) 7,659 Weighted average shares of common stock outstanding—basic 4,182 4,100 4,168 4,095 Dilutive effect of employee equity incentive plans 14 — — 25 Weighted average shares of common stock outstanding—diluted 4,196 4,100 4,168 4,120 Earnings (loss) per share attributable to Intel—basic $ 0.35 $ (0.11) $ (0.31) $ 1.87 Earnings (loss) per share attributable to Intel—diluted $ 0.35 $ (0.11) $ (0.31) $ 1.86

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	6 Months Ended
	Jul. 01, 2023
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Jul 1, 2023 Dec 31, 2022 Raw materials $ 1,284 $ 1,517 Work in process 6,638 7,565 Finished goods 4,062 4,142 Total inventories $ 11,984 $ 13,224
Interest and Other, Net [Table Text Block]	Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Interest income $ 313 $ 98 $ 647 $ 145 Interest expense (214) (109) (407) (233) Other, net 125 (108) 125 966 Total interest and other, net $ 224 $ (119) $ 365 $ 878

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	6 Months Ended
	Jul. 01, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Employee severance and benefit arrangements $ 171 $ 38 $ 132 $ 43 Litigation charges and other 20 13 97 (1,203) Asset impairment charges 9 36 35 36 Total restructuring and other charges $ 200 $ 87 $ 264 $ (1,124)
Schedule of Accrued Restructuring	Restructuring activity for the 2022 Restructuring Program during the first six months of 2023 was as follows: (In Millions) Accrued restructuring balance as of December 31, 2022 $ 873 Additional accruals 101 Adjustments 26 Cash payments (742) Accrued restructuring balance as of July 1, 2023 $ 258

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jul. 01, 2023
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Provision for Income Tax and Effective Tax Rate	Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Income (loss) before taxes $ (816) $ (909) $ (1,974) $ 8,752 Provision for (benefit from) taxes $ (2,289) $ (455) $ (679) $ 1,093 Effective tax rate 280.5 % 50.1 % 34.4 % 12.5 %

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jul. 01, 2023
Investments, Debt and Equity Securities [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of marketable debt investments, by contractual maturity, as of July 1, 2023, was as follows: (In Millions) Fair Value Due in 1 year or less $ 10,441 Due in 1–2 years 1,958 Due in 2–5 years 5,352 Due after 5 years 725 Instruments not due at a single maturity date 1 3,142 Total $ 21,618
Investment [Table Text Block]	(In Millions) Jul 1, 2023 Dec 31, 2022 Marketable equity securities 1 $ 1,295 $ 1,341 Non-marketable equity securities 4,589 4,561 Equity method investments 9 10 Total $ 5,893 $ 5,912 1 Over 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. The trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Ongoing mark-to-market adjustments on marketable equity securities $ (85) $ (209) $ 103 $ (639) Observable price adjustments on non-marketable equity securities — 135 10 206 Impairment charges (38) (44) (74) (67) Sale of equity investments and other 1 99 28 106 4,733 Total gains (losses) on equity investments, net $ (24) $ (90) $ 145 $ 4,233 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions. Net unrealized gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Net unrealized gains (losses) recognized during the period on equity securities $ (26) $ (93) $ 141 $ (337) Less: Net (gains) losses recognized during the period on equity securities sold during the period 28 (19) (7) (11) Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 2 $ (112) $ 134 $ (348)

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jul. 01, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Jul 1, 2023 Dec 31, 2022 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 1,077 $ — $ 1,077 $ — $ 856 $ — $ 856 Financial institution instruments¹ 3,046 1,587 — 4,633 6,899 1,474 — 8,373 Reverse repurchase agreements — 1,700 — 1,700 — 1,301 — 1,301 Short-term investments: Corporate debt — 6,158 — 6,158 — 5,381 — 5,381 Financial institution instruments¹ 96 3,731 — 3,827 196 4,729 — 4,925 Government debt² 49 5,874 — 5,923 48 6,840 — 6,888 Other current assets: Derivative assets 197 963 — 1,160 — 1,264 — 1,264 Loans receivable — 55 — 55 — 53 — 53 Marketable equity securities 1,295 — — 1,295 1,341 — — 1,341 Other long-term assets: Derivative assets — 5 — 5 — 10 — 10 Total assets measured and recorded at fair value $ 4,683 $ 21,150 $ — $ 25,833 $ 8,484 $ 21,908 $ — $ 30,392 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 446 $ 101 $ 547 $ 111 $ 485 $ 89 $ 685 Other long-term liabilities: Derivative liabilities — 722 — 722 — 699 — 699 Total liabilities measured and recorded at fair value $ — $ 1,168 $ 101 $ 1,269 $ 111 $ 1,184 $ 89 $ 1,384 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt.

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jul. 01, 2023
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first six months of 2023 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 31, 2022 $ (299) $ (259) $ (4) $ (562) Other comprehensive income (loss) before reclassifications (191) — 5 (186) Amounts reclassified out of accumulated other comprehensive income (loss) 218 3 — 221 Tax effects (16) — (1) (17) Other comprehensive income (loss) 11 3 4 18 Balance as of July 1, 2023 $ (288) $ (256) $ — $ (544)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	6 Months Ended
	Jul. 01, 2023
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Jul 1, 2023 Dec 31, 2022 Foreign currency contracts $ 27,267 $ 31,603 Interest rate contracts 17,356 16,011 Other 2,058 2,094 Total $ 46,681 $ 49,708
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Jul 1, 2023 Dec 31, 2022 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 144 $ 347 $ 142 $ 290 Interest rate contracts — 798 — 777 Total derivatives designated as hedging instruments $ 144 $ 1,145 $ 142 $ 1,067 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 497 $ 118 $ 866 $ 194 Interest rate contracts 327 6 266 12 Equity contracts 197 — — 111 Total derivatives not designated as hedging instruments $ 1,021 $ 124 $ 1,132 $ 317 Total derivatives $ 1,165 $ 1,269 $ 1,274 $ 1,384 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Jul 1, 2023 Dec 31, 2022 Jul 1, 2023 Dec 31, 2022 Long-term debt $ (11,200) $ (11,221) $ 797 $ 776
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Jul 1, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,070 $ — $ 1,070 $ (548) $ (522) $ — Reverse repurchase agreements 1,700 — 1,700 — (1,700) — Total assets $ 2,770 $ — $ 2,770 $ (548) $ (2,222) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Total liabilities $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Jul 1, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,070 $ — $ 1,070 $ (548) $ (522) $ — Reverse repurchase agreements 1,700 — 1,700 — (1,700) — Total assets $ 2,770 $ — $ 2,770 $ (548) $ (2,222) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Total liabilities $ 1,260 $ — $ 1,260 $ (548) $ (692) $ 20 Dec 31, 2022 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,231 $ — $ 1,231 $ (546) $ (682) $ 3 Reverse repurchase agreements 1,701 — 1,701 — (1,701) — Total assets $ 2,932 $ — $ 2,932 $ (546) $ (2,383) $ 3 Liabilities: Derivative liabilities subject to master netting arrangements $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79 Total liabilities $ 1,337 $ — $ 1,337 $ (546) $ (712) $ 79
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Six Months Ended (In Millions) Location of Gains (Losses) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Foreign currency contracts Interest and other, net $ 211 $ 1,023 $ 212 $ 1,181 Interest rate contracts Interest and other, net 124 31 90 125 Other Various 100 (331) 215 (465) Total $ 435 $ 723 $ 517 $ 841
Interest and other, net [Member] | Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Six Months Ended (In Millions) Jul 1, 2023 Jul 2, 2022 Jul 1, 2023 Jul 2, 2022 Interest rate contracts $ (213) $ (236) $ (21) $ (947) Hedged items 213 236 21 947 Total $ — $ — $ — $ —

Operating Segments (Details)

Operating Segments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Segment Reporting Information [Line Items]
Net revenue	$ 12,949	$ 15,321	$ 24,664	$ 33,674
Operating Income (Loss)	(1,016)	(700)	(2,484)	3,641
Operating Segments
Segment Reporting Information [Line Items]
Net revenue	12,949	15,321	24,664	33,674
Client Computing Group
Segment Reporting Information [Line Items]
Operating Income (Loss)	1,039	876	1,559	3,598
Client Computing Group | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	6,780	7,678	12,547	17,000
Client Computing Group | Desktop | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	2,370	2,289	4,249	4,930
Client Computing Group | Notebook | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	3,896	4,751	7,303	10,710
Client Computing Group | Other | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	514	638	995	1,360
Datacenter and AI
Segment Reporting Information [Line Items]
Operating Income (Loss)	(161)	(80)	(679)	1,313
Datacenter and AI | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	4,004	4,695	7,722	10,769
Network and Edge
Segment Reporting Information [Line Items]
Operating Income (Loss)	(187)	294	(487)	710
Network and Edge | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	1,364	2,211	2,853	4,350
Mobileye
Segment Reporting Information [Line Items]
Operating Income (Loss)	129	190	252	338
Mobileye | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	454	460	912	854
Intel Foundry Services
Segment Reporting Information [Line Items]
Operating Income (Loss)	(143)	(134)	(283)	(157)
Intel Foundry Services | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	232	57	350	213
All other
Segment Reporting Information [Line Items]
Operating Income (Loss)	(1,693)	(1,846)	(2,846)	(2,161)
All other | Operating Segments
Segment Reporting Information [Line Items]
Net revenue	$ 115	$ 220	$ 280	$ 488

Operating Segments - Narrative

Operating Segments - Narrative (Details) $ in Millions	3 Months Ended
	Jul. 02, 2022 USD ($)
Segment Reporting Information [Line Items]
Inventory impairment charge	$ 559

Non-Controlling Interests (Deta

Non-Controlling Interests (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 30, 2023	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Assets		$ 185,629		$ 185,629		$ 182,103
Non-controlling interest		3,454		3,454		1,863
Net Income (Loss) attributable to noncontrolling interest		(8)	$ 0	(18)	$ 0
Mobileye
Noncontrolling Interest [Line Items]
Net proceeds						1,000
Semiconductor Co-Investment Program, Construction Costs | Intel and Brookfield
Noncontrolling Interest [Line Items]
Unrecognized commitment		29,000		$ 29,000
Arizona Fab
Noncontrolling Interest [Line Items]
Percentage of factory output with the right to purchase				100%
Non-controlling interest		1,700		$ 1,700		874
Net Income (Loss) attributable to noncontrolling interest		(3)		(8)
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest		1,800		1,800		$ 1,000
Net Income (Loss) attributable to noncontrolling interest		(5)		$ (10)
Net proceeds		$ 1,600
Conversion of stock, shares converted (in shares)		38,500,000
Conversion of stock, shares converted, percentage of outstanding shares		0.05
Shares issued per share (in dollars per share)		$ 42		$ 42
Non-controlling interest percent held by parent		88%		88%		94%
Mobileye | Common Stock and Capital in Excess of Par Value
Noncontrolling Interest [Line Items]
Increase from subsidiary equity issuance		$ 866
IMS Nanofabrication GmbH (IMS) | Forecast
Noncontrolling Interest [Line Items]
Ownership percentage sold	20%
Variable Interest Entity, Primary Beneficiary | Asset Pledged as Collateral
Noncontrolling Interest [Line Items]
Assets		$ 3,500		$ 3,500		$ 1,800
Variable Interest Entity, Primary Beneficiary | Arizona Fab
Noncontrolling Interest [Line Items]
Interest in variable interest entity				51%
Variable Interest Entity, Not Primary Beneficiary | Arizona Fab
Noncontrolling Interest [Line Items]
Interest in variable interest entity				49%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ 1,473	$ (454)	$ (1,295)	$ 7,659
Less: Net income (loss) attributable to non-controlling interests	(8)	0	(18)	0
Net income (loss) attributable to Intel	$ 1,481	$ (454)	$ (1,277)	$ 7,659
Weighted average shares of common stock outstanding—basic	4,182	4,100	4,168	4,095
Dilutive effect of employee equity incentive plans (shares)	14	0	0	25
Weighted average shares of common stock outstanding—diluted	4,196	4,100	4,168	4,120
Earnings per share - Basic (in dollars per share)	$ 0.35	$ (0.11)	$ (0.31)	$ 1.87
Earnings per share - Diluted (in dollars per share)	$ 0.35	$ (0.11)	$ (0.31)	$ 1.86

Other Financial Statement Det_3

Other Financial Statement Details - Accounts Receivable (Details) $ in Millions	3 Months Ended
	Jul. 01, 2023 USD ($)
Other Financial Statement Details [Abstract]
Accounts receivable sold	$ 1,000

Other Financial Statement Det_4

Other Financial Statement Details - Inventories (Details) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Other Financial Statement Details [Abstract]
Raw materials	$ 1,284	$ 1,517
Work in process	6,638	7,565
Finished goods	4,062	4,142
Total inventories	$ 11,984	$ 13,224

Other Financial Statement Det_5

Other Financial Statement Details - Other Accrued Liabilities (Details) - USD ($) $ in Billions	Jul. 01, 2023	Dec. 31, 2022
Other Financial Statement Details [Abstract]
Deferred compensation	$ 2.7	$ 2.4

Other Financial Statement Det_6

Other Financial Statement Details - Interest and Other, Net (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Dec. 29, 2021	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Other Financial Statement Details [Abstract]
Interest income		$ 313	$ 98	$ 647	$ 145
Interest expense		(214)	(109)	(407)	(233)
Other, net		125	(108)	125	966
Total interest and other, net		224	(119)	365	878
Interest Costs Capitalized		$ (381)	(154)	(744)	(296)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gains on divestitures				$ 0	$ 1,072
NAND Memory Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gains on divestitures	$ 1,000		$ 1,000

Other Financial Statement Det_7

Other Financial Statement Details - Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Jan. 01, 2023	Dec. 31, 2022
Change in Accounting Estimate [Line Items]
Increase to gross margin	$ 4,638	$ 5,587	$ 8,646	$ 14,831
Decrease in R&D expenses	(4,080)	$ (4,400)	(8,189)	$ (8,762)
Decrease in ending inventory	(11,984)		(11,984)			$ (13,224)
Estimated useful life
Change in Accounting Estimate [Line Items]
Increase to gross margin	570		930
Decrease in R&D expenses	110		210
Decrease in ending inventory	$ 910		$ 910
Certain production machinery and equipment
Change in Accounting Estimate [Line Items]
Useful life					8 years	5 years

Restructuring and Other Charg_3

Restructuring and Other Charges - Components (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 171	$ 38	$ 132	$ 43
Litigation charges and other	20	13	97	(1,203)
Asset impairment charges	9	36	35	36
Restructuring and other charges	$ 200	$ 87	$ 264	$ (1,124)

Restructuring and Other Charg_4

Restructuring and Other Charges - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2023	Apr. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Loss Contingencies [Line Items]
Benefit recorded in litigation charges and other	$ (20)		$ (13)	$ (97)	$ 1,203
2022 Restructuring Program
Loss Contingencies [Line Items]
Cumulative restructuring cost	$ 1,200			$ 1,200
EC Fine
Loss Contingencies [Line Items]
Benefit recorded in litigation charges and other		$ 1,200

Restructuring and Other Charg_5

Restructuring and Other Charges - Accrued Restructuring (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Restructuring Cost and Reserve [Line Items]
Additional accruals	$ 255	$ 73
2022 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Accrued restructuring, beginning balance	873
Additional accruals	101
Adjustments	26
Cash payments	(742)
Accrued restructuring, ending balance	$ 258

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Income Tax Disclosure [Abstract]
Income (loss) before taxes	$ (816)	$ (909)	$ (1,974)	$ 8,752
Provision for (benefit from) taxes	$ (2,289)	$ (455)	$ (679)	$ 1,093
Effective tax rate	280.50%	50.10%	34.40%	12.50%

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Realized Gain (Loss)	$ (183,000,000)	$ (1,000,000,000)	$ (91,000,000)	$ (1,300,000,000)
Debt Securities, Available-for-sale, Amortized Cost	6,900,000		6,900,000		$ 10,200,000,000
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative, Amount of Hedged Item	14,700,000,000		14,700,000,000		$ 16,200,000,000
Unrealized Gain (Loss) on Derivatives	$ 237,000,000	$ 868,000,000	$ 124,000,000	$ 1,200,000,000

Investments - Available-for-Sal

Investments - Available-for-Sale Debt Investments (Details) $ in Millions	Jul. 01, 2023 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in 1 year or less	$ 10,441
Due in 1–2 years	1,958
Due in 2–5 years	5,352
Due after 5 years	725
Instruments not due at a single maturity date	3,142
Debt Securities, Available-for-Sale, Total	$ 21,618

Investments - Equity Investment

Investments - Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	$ 1,295		$ 1,295		$ 1,341
Cost Method Investments	4,589		4,589		4,561
Equity Method Investments	9		9		10
Equity Investments	5,893		$ 5,893		$ 5,912
Marketable equity securities subject to trading-volume or market-based restrictions			90%
Marketable equity securities threshold percentage of shares owned resulting in trading volume restrictions			1%
Mark to market on marketable equity securities1	(85)	$ (209)	$ 103	$ (639)
Observable price adjustments on non-marketable	0	135	10	206
Impairments	(38)	(44)	(74)	(67)
Other Net Equity Investments	99	28	106	4,733
Gain (Loss) on Investments	(24)	(90)	145	4,233
Net unrealized gains (losses) recognized during the period on equity securities	(26)	(93)	141	(337)
Less: Net (gains) losses recognized during the period on equity securities sold during the period	28	(19)	(7)	(11)
Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	$ 2	$ (112)	$ 134	$ (348)

Investments - Equity Investme_2

Investments - Equity Investments, Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Schedule of Equity Method Investments [Line Items]
Special dividend recognized in sale of equity investments and other	$ 99	$ 28	$ 106	$ 4,733
McAfee
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investment	$ 4,600

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ (24)	$ (90)	$ 145	$ 4,233

Acquisitions and Divestitures (

Acquisitions and Divestitures (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended			6 Months Ended
	Dec. 29, 2021	Oct. 19, 2020	Mar. 30, 2024	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022	Oct. 31, 2020
Business Acquisition [Line Items]
Proceeds from divestiture						$ 0	$ 6,579
Gains on divestitures						0	1,072
Income Tax Expense (Benefit)				$ (2,289)	$ (455)	(679)	$ 1,093
Goodwill				27,591		27,591		$ 27,591
Receivable recorded in other current assets				4,119		4,119		$ 4,712
Affiliated Entity | NAND Memory Business Divestiture
Business Acquisition [Line Items]
Receivable recorded in other current assets				201		201
NAND Memory Business
Business Acquisition [Line Items]
Consideration transferred for divestiture of business		$ 9,000
Proceeds from divestiture	$ 7,000
Gains on divestitures	1,000				$ 1,000
Income Tax Expense (Benefit)	$ 495
Maximum exposure annually									$ 500
Maximum exposure									$ 1,500
Nontrade Receivables, Noncurrent				$ 1,900		$ 1,900
Forecast | Affiliated Entity | NAND Memory Business Divestiture
Business Acquisition [Line Items]
Quarterly expense reimbursement			$ 32
Tower | Forecast
Business Acquisition [Line Items]
Cash paid per acquiree share (in dollars per share)			$ 53
Total enterprise value			$ 5,400
Termination fee upon failure to obtain required regulatory approvals			$ 353

Borrowings Borrowings - Narrati

Borrowings Borrowings - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Apr. 01, 2023	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Commercial paper settled in cash	$ 3,900,000,000		$ 3,944,000,000	$ 0
Commercial paper outstanding					$ 3,900,000,000
Repayments of Long-term Debt			0	1,688,000,000
Proceeds from issuance of debt			10,968,000,000	$ 0
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 10,000,000,000		$ 10,000,000,000
Variable Rate Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Term of debt		5 years
Variable rate revolving credit facility		$ 5,000,000,000
Senior Notes
Debt Instrument [Line Items]
Face amount of debt issued		$ 11,000,000,000
Line of Credit | Credit Facility Agreement
Debt Instrument [Line Items]
Term of debt		364 days
Maximum borrowing capacity		$ 5,000,000,000

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 1,700	$ 1,701
Derivative assets, Fair Value Disclosure	1,070	1,231
Derivative liabilities, Fair Value Disclosure	1,260	1,337
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	25,833	30,392
Liabilities, Fair Value Disclosure	1,269	1,384
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	512	437
Short-term and Long-term Debt, Fair Value	45,400	34,300
Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,295	1,341
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,700	1,301
Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,077	856
Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,633	8,373
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,158	5,381
Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,827	4,925
Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,923	6,888
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	1,160	1,264
Loans receivable, Fair Value Disclosure	55	53
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	5	10
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	547	685
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	722	699
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	4,683	8,484
Liabilities, Fair Value Disclosure	0	111
Level 1 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,295	1,341
Level 1 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,046	6,899
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	96	196
Level 1 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	49	48
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	197	0
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	111
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	21,150	21,908
Liabilities, Fair Value Disclosure	1,168	1,184
Level 2 [Member] | Fair Value, Nonrecurring [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements		400
Level 2 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 2 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,700	1,301
Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,077	856
Level 2 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,587	1,474
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,158	5,381
Level 2 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,731	4,729
Level 2 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,874	6,840
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	963	1,264
Loans receivable, Fair Value Disclosure	55	53
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	5	10
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	446	485
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	722	699
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	101	89
Level 3 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	101	89
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss), Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Apr. 01, 2023	Dec. 31, 2022	Apr. 02, 2022	Dec. 25, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months			$ 110
Accumulated other comprehensive income (loss)	$ 104,471	$ 101,218	104,471	$ 101,218	$ 100,403	$ 103,286	$ 103,136	$ 95,391
Other comprehensive income (loss)	(125)	$ (623)	18	$ (745)
Unrealized holding gains (losses) on available-for-sale investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	(288)		(288)			(299)
Other comprehensive income (loss) before reclassifications			(191)
Amounts reclassified out of accumulated other comprehensive income (loss)			218
Tax effects			(16)
Other comprehensive income (loss)			11
Unrealized holding gains (losses) on derivatives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	(256)		(256)			(259)
Other comprehensive income (loss) before reclassifications			0
Amounts reclassified out of accumulated other comprehensive income (loss)			3
Tax effects			0
Other comprehensive income (loss)			3
Actuarial gains (losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	0		0			(4)
Other comprehensive income (loss) before reclassifications			5
Amounts reclassified out of accumulated other comprehensive income (loss)			0
Tax effects			(1)
Other comprehensive income (loss)			4
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	$ (544)		(544)			$ (562)
Other comprehensive income (loss) before reclassifications			(186)
Amounts reclassified out of accumulated other comprehensive income (loss)			221
Tax effects			(17)
Other comprehensive income (loss)			$ 18

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2023	Apr. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Notional Disclosures [Abstract]
Notional amount	$ 46,681			$ 46,681		$ 49,708
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,070			1,070		1,231
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0			0		0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,070			1,070		1,231
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(548)			(548)		(546)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(522)			(522)		(682)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	0			0		3
Reverse Repurchase Agreements, Gross Amounts Recognized	1,700			1,700		1,701
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0			0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	1,700			1,700		1,701
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0			0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(1,700)			(1,700)		(1,701)
Reverse Repurchase Agreements, Net Amount	0			0		0
Total Assets, Gross Amounts Recognized	2,770			2,770		2,932
Total Assets, Gross Amounts Offset in the Balance Sheet	0			0		0
Total Assets, Net Amounts Presented in the Balance Sheet	2,770			2,770		2,932
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(548)			(548)		(546)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(2,222)			(2,222)		(2,383)
Total Assets, Net Amount	0			0		3
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,260			1,260		1,337
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0			0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,260			1,260		1,337
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(548)			(548)		(546)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(692)			(692)		(712)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	20			20		79
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	213		$ 236	21	$ 947
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0		0	0	0
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,165			1,165		1,274
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,269			1,269		1,384
Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	144			144		142
Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,145			1,145		1,067
Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	435		723	517	841
Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,021			1,021		1,132
Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	124			124		317
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	27,267			27,267		31,603
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Before-tax net gains (losses) attributed to cash flow hedges, recognized in other comprehensive income (loss)	(245)		(782)	(191)	(897)
Foreign currency contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	144			144		142
Foreign currency contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	347			347		290
Foreign currency contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	211		1,023	212	1,181
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	497			497		866
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	118			118		194
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	17,356			17,356		16,011
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(213)		(236)	(21)	(947)
Interest rate contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	0			0		0
Interest rate contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	798			798		777
Interest rate contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	124		31	90	125
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	327			327		266
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	6			6		12
Other
Notional Disclosures [Abstract]
Notional amount	2,058			2,058		2,094
Other | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	100		$ (331)	215	$ (465)
Other | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	197			197		0
Other | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	0			0		111
Interest Rate Swap | Long-term Debt | Fair Value Hedging
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000			12,000
Derivative, Fair Value, Net	$ (11,200)			(11,200)		$ (11,221)
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives		$ 776		$ 797

Contingencies (Detail)

Contingencies (Detail) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Loss Contingencies [Line Items]
Finance lease prepayments	$ 96	$ 299